Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study
Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in a key study of an aggressive form of breast cancer. Gilead announced Monday that ...
